UNSPSC 51362403: Triclofos

This classification denotes a sedative and hypnotic with the molecular formula C2H4Cl3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J712EO9048, chemically known as 2,2,2-trichloroethyl phosphate but generally known as triclofos, which bears US NIH Compound Identifier 5563. European Medicines Agency schedules Triclofos in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11274MIG.

UNSPSC 51362403 Triclofos, a Commodity code, maps nominally to a single pharmaceutical product but does not align with the actual scope of recent state and local procurement activity tagged under this code. The recent solicitations show state and local governments buying naloxone (opioid reversal agent), safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and investigating direct-to-manufacturer prescription programs—none of which are triclofos-specific procurements. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance). The geographic spread includes Florida, Texas, Minnesota, and Oregon across the recent opportunities identified.

The most recent labeled opportunity is Seminole County, Florida's IFB60459723LAS, an Invitation for Bid posted June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source). The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. The Texas HHS Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit managers and group purchasing organizations. The code shows little relevant recent activity specifically aligned to triclofos; the mismatch suggests either a tagging error or that triclofos procurement, if occurring under this code, is not surfacing in recent state and local solicitations.